Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Charles River Laboratories

Healthcare US CRL

167.37USD
-9.62(5.44%)

Last update at 2026-03-10T20:00:00Z

Day Range

166.82175.28
LowHigh

52 Week Range

161.65262.00
LowHigh

Fundamentals

  • Previous Close 176.99
  • Market Cap12117.84M
  • Volume793459
  • P/E Ratio25.57
  • Dividend Yield2.40%
  • EBITDA972.45M
  • Revenue TTM4215.78M
  • Revenue Per Share TTM82.46
  • Gross Profit TTM 1462.65M
  • Diluted EPS TTM9.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 622.99M 480.71M 447.11M 304.08M 281.68M
Minority interest 6.38M 7.86M 1.00M 2.04M 2.35M
Net income 486.23M 390.98M 364.30M 252.02M 226.37M
Selling general administrative 665.10M 619.92M 528.93M 486.20M 419.72M
Selling and marketing expenses - - - - -
Gross profit 1462.65M 1334.64M 1073.54M 958.31M 840.07M
Reconciled depreciation 303.87M 265.54M 234.92M 198.09M 161.78M
Ebit 650.98M 589.86M 432.73M 351.15M 345.45M
Ebitda 986.15M 820.16M 768.47M 563.06M 410.28M
Depreciation and amortization 335.17M 230.30M 335.74M 211.91M 64.83M
Non operating income net other 31.30M -35.24200M 100.82M 13.81M 14.07M
Operating income 650.98M 589.86M 432.73M 351.15M 331.38M
Other operating expenses 3325.09M 2950.30M 2491.20M 2270.07M 1934.71M
Interest expense 59.29M 73.91M 86.43M 60.88M 63.77M
Tax provision 130.38M 81.87M 81.81M 50.02M 54.46M
Interest income 0.78M 74.86M 0.83M 1.52M 0.81M
Net interest income -58.51100M -73.25800M -85.59900M -59.36000M -62.96000M
Extraordinary items - - - 0.00000M 7.01M
Non recurring - - - - -
Other items - - - - -
Income tax expense 130.38M 81.87M 81.81M 50.02M 54.46M
Total revenue 3976.06M 3540.16M 2923.93M 2621.23M 2266.10M
Total operating expenses 811.68M 744.78M 640.81M 607.16M 508.68M
Cost of revenue 2513.41M 2205.52M 1850.39M 1662.91M 1426.03M
Total other income expense net -27.98800M -109.15200M 14.38M -47.06700M 13.26M
Discontinued operations - - - - 1.51M
Net income from continuing ops 492.61M 398.84M 365.31M 254.06M 227.22M
Net income applicable to common shares 486.23M 390.98M 364.30M 252.02M 226.37M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 7602.77M 7024.29M 5490.83M 4692.79M 3855.88M
Intangible assets 955.27M 1061.19M 787.60M 689.41M 610.89M
Earning assets - - - - -
Other current assets 107.58M 97.31M 72.56M 56.03M 48.81M
Total liab 4579.27M 4432.30M 3347.16M 3026.32M 2517.58M
Total stockholder equity 2976.29M 2534.82M 2114.60M 1634.58M 1317.33M
Deferred long term liab 215.58M 239.72M 217.03M 167.28M 143.63M
Other current liab 621.41M 612.56M 459.12M 388.33M 315.42M
Common stock 0.51M 0.51M 0.50M 0.49M 0.48M
Capital stock 0.51M 0.51M 0.50M 0.49M 0.48M
Retained earnings 1432.90M 980.75M 625.41M 280.33M 42.10M
Other liab 390.40M 482.58M 422.25M 350.22M 322.76M
Good will 2849.90M 2711.88M 1809.17M 1540.57M 1247.13M
Other assets 0.00100M -47.21100M 1459.35M 134.29M 78.55M
Cash 233.91M 241.21M 228.42M 238.01M 195.44M
Cash and equivalents 233.91M 241.21M 228.42M 238.01M 195.44M
Total current liabilities 1091.59M 1033.18M 839.75M 710.18M 558.22M
Current deferred revenue 264.26M 219.70M 207.94M 171.81M 145.14M
Net debt 2863.36M 2678.12M 1906.96M 1766.45M 1472.57M
Short term debt 0.00000M 2.79M 50.21M 38.55M 31.42M
Short long term debt - 0.10M 47.20M 35.55M 31.42M
Short long term debt total 3097.28M 2919.33M 2135.38M 2004.46M 1668.01M
Other stockholder equity 1804.94M 1718.30M 1627.56M 1531.79M 1447.46M
Property plant equipment 1857.42M 1584.01M 1124.36M 1044.13M 932.88M
Total current assets 1439.03M 1274.10M 1201.13M 1021.33M 897.84M
Long term investments 311.60M 201.35M 221.80M 122.98M 88.59M
Net tangible assets -786.45800M -1185.24300M -456.66600M -566.74700M -522.16400M
Short term investments 1.00M 1.06M 1.02M 0.94M 0.89M
Net receivables 752.39M 642.88M 617.74M 514.03M 472.25M
Long term debt 2707.53M 2639.03M 1903.54M 1822.14M 1636.60M
Inventory 255.81M 199.15M 185.69M 160.66M 127.89M
Accounts payable 205.91M 198.13M 122.47M 111.50M 66.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 4.79M 4.16M 3.57M 3.24M 2.45M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -262.05700M -164.74000M -138.87400M -178.01900M -172.70300M
Additional paid in capital - - - - -
Common stock total equity 0.51M 0.51M 0.50M 0.49M 0.48M
Preferred stock total equity - - - - -
Retained earnings total equity 1432.90M 980.75M 625.41M 280.33M 42.10M
Treasury stock - - - - -0.05500M
Accumulated amortization - - - - -
Non currrent assets other 148.28M 151.54M 130.82M 89.64M 55.17M
Deferred long term asset charges - - - - -
Non current assets total 6163.74M 5750.20M 4289.70M 3671.47M 2958.04M
Capital lease obligations 389.75M 316.16M 209.32M 167.14M -
Long term debt total 2707.53M 2663.56M 1929.57M 1849.67M 1636.60M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -153.72500M -39.02300M -15.29100M -21.39900M 10.72M
Change to liabilities -44.81600M 89.20M 41.23M 33.17M 9.91M
Total cashflows from investing activities -607.92200M -1437.93200M -601.54400M -681.50200M -955.00300M
Net borrowings 19.79M 669.98M 30.59M 227.28M 535.69M
Total cash from financing activities -42.39700M 672.60M 47.25M 231.94M 558.06M
Change to operating activities -8.92400M 46.31M 39.38M 20.64M -2.10700M
Net income 492.61M 398.84M 365.31M 254.06M 227.22M
Change in cash -5.10000M 13.20M -6.92700M 42.73M 30.99M
Begin period cash flow 246.31M 233.12M 240.05M 197.32M 166.33M
End period cash flow 241.21M 246.31M 233.12M 240.05M 197.32M
Total cash from operating activities 619.64M 760.80M 546.58M 480.94M 441.14M
Issuance of capital stock - - - - -
Depreciation 303.87M 265.54M 234.92M 198.09M 161.78M
Other cashflows from investing activities -129.46400M -1170.13700M -419.69300M -519.58900M -825.67300M
Dividends paid - - - - -
Change to inventory -78.52300M -25.15900M -18.37900M -21.39900M -13.33800M
Change to account receivables -150.57000M -26.63300M -85.62700M -8.32300M -21.19600M
Sale purchase of stock -38.65100M -40.70700M -23.97900M -18.08700M -13.84600M
Other cashflows from financing activities 2903.78M 6956.18M 2271.63M 3374.61M 2772.91M
Change to netincome -51.05900M 23.06M 73.48M 22.60M 33.59M
Capital expenditures 324.73M 228.77M 166.56M 140.51M 140.05M
Change receivables -150.57000M -26.63300M -85.62700M -8.32300M -21.19600M
Cash flows other operating 148.13M 35.95M 300.95M 256.79M 266.66M
Exchange rate changes - - - - -
Cash and cash equivalents changes -30.67900M -4.53500M -7.72100M 31.37M 44.20M
Change in working capital -152.55400M 42.94M -26.27500M 6.18M 14.81M
Stock based compensation 73.62M 71.47M 56.34M 57.27M 47.35M
Other non cash items -62.01700M 6.01M -83.58800M -12.77500M -0.31500M
Free cash flow 294.91M 532.03M 380.01M 340.42M 301.09M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRL
Charles River Laboratories		 -9.62 5.44% 167.37 25.57 20.12 2.82 3.59 3.47 13.72
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories

251 Ballardvale Street, Wilmington, MA, United States, 01887

Key Executives

Name Title Year Born
Mr. James C. Foster J.D. Chairman, CEO & Pres 1951
Ms. Birgit Girshick Corp. Exec. VP & COO 1970
Mr. Joseph W. LaPlume Corp. Exec. VP of Corp. Devel. & Strategy 1974
Mr. William D. Barbo Chief Commercial Officer & Corp. Exec. VP 1961
Mr. David Ross Smith Sr. Financial Advisor 1966
Ms. Flavia H. Pease Corp. Exec. VP & CFO NA
Mr. Michael Gunnar Knell Corp. Sr. VP & Chief Accounting Officer 1977
Prof. Julie Frearson Ph.D. Corp. Sr. VP & Chief Scientific Officer NA
Mr. Mark Mintz Corp. Sr. VP & Chief Information Officer NA
Todd Spencer Corp. VP of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.